Literature DB >> 18317212

Morphological effects of radiochemotherapy on cervical carcinoma: a morphological study of 50 cases of hysterectomy specimens after neoadjuvant treatment.

Gian Franco Zannoni1, Valerio Gaetano Vellone, Arnaldo Carbone.   

Abstract

The introduction of radiochemotherapy for treatment of advanced cervical cancers represents a new chapter in surgical pathology. The study group included 50 women with a histological diagnosis of advanced cervical carcinoma (43 squamous, 3 adenosquamous, 2 adenocarcinoma, 1 glassy cell, and 1 undifferentiated; International Federation of Gynecology and Obstetrics stage Ib-III) receiving a platinum-based chemotherapy concomitant with external beam radiotherapy before radical surgery. We evaluated the amount of residual neoplastic tissue, depth of invasion, presence of neoplastic embolism, number of metastatic lymph nodes, and alterations of the nonneoplastic stroma and epithelium. We observed neoplastic masses larger than 0.3 cm (no pathological response, pR2) in 14 cases (28%), single or multiple microscopic neoplastic residual (partial pathological response, pR1) in 24 cases (48%), and no invasive neoplastic cells (complete pathological response, pR0) in 12 cases (24%). Residual neoplastic cells showed a wide pattern of alterations such as cytoplasmic eosinophilia, vacuolation, and foamy appearance; the nuclei were enlarged and irregular with clumped chromatin. The mitotic activity was scanty. In some cases, multinucleated neoplastic giant cell coexisted with reactive foreign body-like giant cells. The stroma was fibrous containing inflammatory cells, fibrinous debris, cholesterol clefts, hemosiderin pigments, and microcalcifications. In just 2 cases, we found lymph node metastases. The pathologist has to distinguish neoplastic residuals from reactive changes. In most cases, morphological criteria are sufficient to make a diagnosis, but sometimes, the use of immunohistochemistry (keratins and CD68) is a mandatory method to reveal the nature of the lesion.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18317212     DOI: 10.1097/PGP.0b013e31815b1263

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  11 in total

1.  The PRICE study: The role of conventional and diffusion-weighted magnetic resonance imaging in assessment of locally advanced cervical cancer patients administered by chemoradiation followed by radical surgery.

Authors:  A L Valentini; M Miccò; B Gui; M Giuliani; E Rodolfino; A M Telesca; T Pasciuto; A Testa; M A Gambacorta; G Zannoni; V Rufini; A Giordano; V Valentini; G Scambia; R Manfredi
Journal:  Eur Radiol       Date:  2018-01-09       Impact factor: 5.315

2.  Posttherapy residual disease associates with long-term survival after chemoradiation for bulky stage 1B cervical carcinoma: a Gynecologic Oncology Group study.

Authors:  Charles Kunos; Shamshad Ali; Fadi W Abdul-Karim; Frederick B Stehman; Steven Waggoner
Journal:  Am J Obstet Gynecol       Date:  2010-06-11       Impact factor: 8.661

3.  The role of 18F-FDG-PET/CT in predicting the histopathological response in locally advanced cervical carcinoma treated by chemo-radiotherapy followed by radical surgery: a prospective study.

Authors:  Vittoria Rufini; Angela Collarino; Maria Lucia Calcagni; Guido Maria Meduri; Valentina Fuoco; Tina Pasciuto; Antonia Carla Testa; Gabriella Ferrandina; Maria Antonietta Gambacorta; Maura Campitelli; Benedetta Gui; Gianfranco Zannoni; Riccardo Manfredi; Giovanni Scambia; Alessandro Giordano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-14       Impact factor: 9.236

4.  Dual Inhibitor AEE788 Reduces Tumor Growth in Preclinical Models of Medulloblastoma.

Authors:  Daniela Meco; Tiziana Servidei; Gian Franco Zannoni; Enrica Martinelli; Maria Grazia Prisco; Chiara de Waure; Riccardo Riccardi
Journal:  Transl Oncol       Date:  2010-10-01       Impact factor: 4.243

5.  Gastric-type mucinous adenocarcinoma of the uterine cervix with neoadjuvant therapy mimicking clear cell carcinoma.

Authors:  Yifen Zhang; Li Liang; Elizabeth D Euscher; Jinsong Liu; Preetha Ramalingam
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

6.  Prognostic value of pathological response to neoadjuvant chemotherapy in bulky stage Ib2 and IIa cervical squamous cell cancer patients.

Authors:  Yun Liang; Bingjian Lü; Xiaoduan Chen; Jiale Qin; Xiaodong Cheng; Xing Xie; Weiguo Lü
Journal:  Virchows Arch       Date:  2015-12-04       Impact factor: 4.064

7.  Assessing Post-Treatment Pathologic Tumor Response in Female Genital Tract Carcinomas: An Update.

Authors:  Frediano Inzani; Damiano Arciuolo; Giuseppe Angelico; Angela Santoro; Antonio Travaglino; Nicoletta D'Alessandris; Giulia Scaglione; Michele Valente; Federica Cianfrini; Antonio Raffone; Gian Franco Zannoni
Journal:  Front Oncol       Date:  2022-02-10       Impact factor: 6.244

8.  Polarisation of Tumor-Associated Macrophages toward M2 Phenotype Correlates with Poor Response to Chemoradiation and Reduced Survival in Patients with Locally Advanced Cervical Cancer.

Authors:  Marco Petrillo; Gian Franco Zannoni; Enrica Martinelli; Luigi Pedone Anchora; Gabriella Ferrandina; Giovanna Tropeano; Anna Fagotti; Giovanni Scambia
Journal:  PLoS One       Date:  2015-09-03       Impact factor: 3.240

9.  The relevance of prelamin A and RAD51 as molecular biomarkers in cervical cancer.

Authors:  Simona Leonardi; Marianna Buttarelli; Ilaria De Stefano; Gabriella Ferrandina; Marco Petrillo; Gabriele Babini; Giovanni Scambia; Carmela Marino; Mariateresa Mancuso; Daniela Gallo
Journal:  Oncotarget       Date:  2017-10-09

10.  Pretreatment MRI Radiomics Based Response Prediction Model in Locally Advanced Cervical Cancer.

Authors:  Benedetta Gui; Rosa Autorino; Maura Miccò; Alessia Nardangeli; Adele Pesce; Jacopo Lenkowicz; Davide Cusumano; Luca Russo; Salvatore Persiani; Luca Boldrini; Nicola Dinapoli; Gabriella Macchia; Giuseppina Sallustio; Maria Antonietta Gambacorta; Gabriella Ferrandina; Riccardo Manfredi; Vincenzo Valentini; Giovanni Scambia
Journal:  Diagnostics (Basel)       Date:  2021-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.